Fig. 4
From: CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin
Activity evaluation of E8-PE38 immunotoxin in vitro and in vivo. a SDS-PAGE analysis of purified E8 nanobody (16 kDa), E8-PE38 (60 kDa) and Con-PE38 (60 kDa). b SPR analysis of E8-PE38 binding to CDH17. The KD was 86.87 nM. c Cell viability detection after treatment with E8 nanobody alone, E8-PE38 and Con-PE38 in MKN45, TMK1, AGS and IM95 cells (n = 3, ****p < 0.0001, two-way ANOVA). Dashed line indicated the IC50 for E8-PE38 immunotoxin. d Schema of animal treatment schedule. e MKN45 tumor growth curves with the treatment of PBS, 0.4 or 0.6 mg/kg E8-PE38 (n = 4-5 per group, **P < 0.01, ***P < 0.001, two-way ANOVA). Mice were euthanized when tumor size reached 2000 mm3. f Individual tumor growth curves for three groups in e. g Body weight during the treatment from three groups in e. h Survival curves for treated mice in e (**p < 0.01, Log-rank (Mantel-Cox) test)